RNAC
Price
$6.41
Change
-$0.01 (-0.16%)
Updated
Oct 22 closing price
Capitalization
193.94M
13 days until earnings call
Intraday BUY SELL Signals
VBIO
Price
$0.96
Change
-$0.16 (-14.29%)
Updated
Oct 22 closing price
Capitalization
848.62K
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RNAC vs VBIO

RNAC vs VBIO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
RNAC vs. VBIO commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RNAC is a Buy and VBIO is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for RNAC with price predictions
Oct 22, 2026

RNAC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 14, 2026

RNAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 44 cases where RNAC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RNAC's RSI Oscillator exited the oversold zone, 32 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 65 cases where RNAC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for RNAC just turned positive on October 21, 2026. Looking at past instances where RNAC's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.

Following a +5.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNAC advanced for three days, in 218 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for RNAC entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.549) is normal, around the industry mean (2.973). P/E Ratio (-1.109) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (144.928) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. RNAC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for VBIO with price predictions
Oct 22, 2026

VBIO's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for VBIO turned positive on September 29, 2026. Looking at past instances where VBIO's MACD turned positive, the stock continued to rise in 36 of 39 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +39.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where VBIO advanced for three days, in 167 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

VBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VBIO as a result. In 89 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for VBIO entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.200) is normal, around the industry mean (2.973). P/E Ratio (-0.005) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.510) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. VBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 99 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
RNAC vs VBIO: Fundamental Ratings
RNAC
VBIO
OUTLOOK RATING
1..100
6453
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
67
Overvalued
PROFIT vs RISK RATING
1..100
10099
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
7798
P/E GROWTH RATING
1..100
1998
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RNAC's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for VBIO (67) in the null industry. This means that RNAC’s stock grew somewhat faster than VBIO’s over the last 12 months.

VBIO's Profit vs Risk Rating (99) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that VBIO’s stock grew similarly to RNAC’s over the last 12 months.

VBIO's SMR Rating (100) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that VBIO’s stock grew similarly to RNAC’s over the last 12 months.

RNAC's Price Growth Rating (77) in the Biotechnology industry is in the same range as VBIO (98) in the null industry. This means that RNAC’s stock grew similarly to VBIO’s over the last 12 months.

RNAC's P/E Growth Rating (19) in the Biotechnology industry is significantly better than the same rating for VBIO (98) in the null industry. This means that RNAC’s stock grew significantly faster than VBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RNACVBIO
RSI
ODDS (%)
Bullish Trend 1 day ago
74%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 29 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (RNAC: $6.41 vs. VBIO: $0.96)
Brand notoriety: RNAC and VBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RNAC: 70% vs. VBIO: 15%
Market capitalization -- RNAC: $193.94M vs. VBIO: $848.62K
RNAC [@Biotechnology] is valued at $193.94M. VBIO’s [@Biotechnology] market capitalization is $848.62K. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RNAC’s FA Score shows that 2 FA rating(s) are green while VBIO’s FA Score has 0 green FA rating(s).

  • RNAC’s FA Score: 2 green, 3 red.
  • VBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, RNAC is a better buy in the long-term than VBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RNAC’s TA Score shows that 5 TA indicator(s) are bullish while VBIO’s TA Score has 4 bullish TA indicator(s).

  • RNAC’s TA Score: 5 bullish, 2 bearish.
  • VBIO’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, RNAC is a better buy in the short-term than VBIO.

Price Growth

RNAC (@Biotechnology) experienced а -2.58% price change this week, while VBIO (@Biotechnology) price change was -22.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

RNAC is expected to report earnings on Nov 05, 2026.

VBIO is expected to report earnings on Nov 13, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
RNAC
Daily Signal:
Gain/Loss:
VBIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-0.16%
TAOX - RNAC
91%
Closely correlated
-5.50%
PALI - RNAC
81%
Closely correlated
-3.57%
EDIT - RNAC
46%
Loosely correlated
-0.80%
NKTX - RNAC
45%
Loosely correlated
-0.57%
SLDB - RNAC
41%
Loosely correlated
-3.43%
More

VBIO and

Correlation & Price change

A.I.dvisor tells us that VBIO and DARE have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VBIO and DARE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VBIO
1D Price
Change %
VBIO100%
-14.63%
DARE - VBIO
25%
Poorly correlated
-5.28%
SNGX - VBIO
25%
Poorly correlated
+0.30%
BMEA - VBIO
23%
Poorly correlated
-15.23%
ENLV - VBIO
23%
Poorly correlated
-1.48%
BNTC - VBIO
23%
Poorly correlated
+3.76%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NMB23.740.30
+1.26%
Simplify National Muni Bond ETF (NMB)
SPCK21.600.15
+0.70%
SPAC and New Issue ETF (SPCK)
DEM53.87-0.92
-1.68%
WisdomTree Emerging Markets High Dividend Fund (DEM)
FNY97.06-1.67
-1.69%
First Trust Mid Cap Growth AlphaDEX Fund (FNY)
TSLT13.85-0.88
-5.97%
T-REX 2X Long Tesla Daily Target ETF (TSLT)